SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-21-002528
Filing Date
2021-03-10
Accepted
2021-03-10 08:49:23
Documents
8
Period of Report
2021-03-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT azrx8k_mar72021.htm 8-K 44719
2 FORM OF PRE-FUNDED WARRANT ex4-1.htm EX-4 114292
3 FORM OF WARRANT ex4-2.htm EX-4.2 113787
4 FORM OF WAINWRIGHT WARRANT ex4-3.htm EX-4.3 111168
5 OPINION OF LOWENSTEIN SANDLER LLP ex5-1.htm EX-5 13671
6 FORM OF PURCHASE AGREEMENT ex10-1.htm EX-10 247995
7 PRESS RELEASE ex99-1.htm EX-99 14539
8 IMAGE image.jpg GRAPHIC 7171
  Complete submission text file 0001654954-21-002528.txt   671475
Mailing Address 1615 SOUTH CONGRESS AVENUE SUITE 103 DELRAY BEACH FL 33445
Business Address 1615 SOUTH CONGRESS AVENUE SUITE 103 DELRAY BEACH FL 33445 646-699-7855
AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 21728362
SIC: 2834 Pharmaceutical Preparations